ARCHIVES

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III

December 31, 2010

NCI Cooperative Group, Cancer Center Trials Listed

February 27, 2009

Capitated Oncology Becomes Marketplace Reality Wit Plan By Companies

January 14, 1994

Clinical Trial Participants Sue Duke University, Potti, Nevins and Others for Causing Harm

September 9, 2011

Science Policy: Second-Hand Smoke Linked To Lung Cancer, Other Health Effects

November 26, 1999

Funding Opportunities.

July 19, 2002